Roivant Sciences (NASDAQ:ROIV) CEO Sells $37,723,200.00 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Matthew Gline sold 1,740,000 shares of the firm’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $21.68, for a total value of $37,723,200.00. Following the completion of the sale, the chief executive officer owned 17,290,820 shares of the company’s stock, valued at approximately $374,864,977.60. This represents a 9.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Matthew Gline also recently made the following trade(s):

• On Thursday, September 18th, Matthew Gline bought 3,315 shares of Roivant Sciences stock. The shares were bought at an average cost of $15.07 per share, with a total value of $49,957.05.

Roivant Sciences Trading Down 1.0%

Shares of NASDAQ ROIV traded down $0.24 during mid-day trading on Wednesday, reaching $22.70. The company had a trading volume of 12,370,038 shares, compared to its average volume of 7,275,131. The stock has a market cap of $15.79 billion, a price-to-earnings ratio of -40.54 and a beta of 1.22. The business’s 50-day moving average is $19.76 and its 200-day moving average is $14.95. Roivant Sciences Ltd. has a 52 week low of $8.73 and a 52 week high of $23.47.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Weiss Ratings upgraded Roivant Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Saturday, October 25th. Leerink Partners lifted their price objective on shares of Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a research report on Monday. Jefferies Financial Group boosted their price objective on shares of Roivant Sciences from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, September 18th. JPMorgan Chase & Co. raised their target price on shares of Roivant Sciences from $16.00 to $20.00 and gave the company an “overweight” rating in a research note on Thursday, September 18th. Finally, HC Wainwright raised their price target on Roivant Sciences from $23.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, December 12th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.81.

Institutional Trading of Roivant Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Jones Financial Companies Lllp grew its stake in shares of Roivant Sciences by 226.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock valued at $25,000 after buying an additional 1,148 shares during the period. Allworth Financial LP increased its stake in Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after acquiring an additional 583 shares during the last quarter. Bessemer Group Inc. lifted its position in Roivant Sciences by 41.5% in the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after buying an additional 543 shares during the last quarter. CWM LLC raised its stake in shares of Roivant Sciences by 44.6% in the 2nd quarter. CWM LLC now owns 2,984 shares of the company’s stock valued at $34,000 after acquiring an additional 920 shares during the period. Finally, Russell Investments Group Ltd. lifted its holdings in shares of Roivant Sciences by 94.8% in the 1st quarter. Russell Investments Group Ltd. now owns 4,588 shares of the company’s stock worth $46,000 after acquiring an additional 2,233 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.